

Andreas Hättmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8248934/publications.pdf>

Version: 2024-02-01

74
papers

4,388
citations

147786

31
h-index

110368

64
g-index

75
all docs

75
docs citations

75
times ranked

5550
citing authors

#	ARTICLE	IF	CITATIONS
1	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 229-240.	13.7	517
2	Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. <i>Blood</i> , 2012, 120, 2032-2041.	1.4	381
3	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. <i>Lancet Oncology, The</i> , 2015, 16, 1691-1699.	10.7	347
4	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 2845-2853.	1.6	313
5	PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. <i>Lancet, The</i> , 2017, 390, 2790-2802.	13.7	274
6	Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. <i>Blood</i> , 2014, 124, 3870-3879.	1.4	236
7	Positron Emission Tomographyâ€“Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2024-2034.	1.6	176
8	Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 536-543.	1.6	168
9	High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. <i>Blood</i> , 2011, 118, 3504-3511.	1.4	158
10	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. <i>Nature Biotechnology</i> , 2021, 39, 1537-1547.	17.5	151
11	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. <i>Cell</i> , 2019, 178, 699-713.e19.	28.9	138
12	Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma. <i>JAMA Oncology</i> , 2020, 6, 872.	7.1	112
13	Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. <i>Blood</i> , 2009, 113, 3885-3886.	1.4	97
14	PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 223-234.	10.7	93
15	Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). <i>Journal of Clinical Oncology</i> , 2022, 40, 242-251.	1.6	90
16	Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. <i>Blood</i> , 2003, 101, 2748-2755.	1.4	77
17	Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. <i>Blood Advances</i> , 2018, 2, 2543-2549.	5.2	74
18	Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. <i>European Journal of Cancer</i> , 2020, 124, 25-36.	2.8	67

#	ARTICLE	IF	CITATIONS
19	Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. <i>Annals of Hematology</i> , 2012, 91, 243-248.	1.8	59
20	Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation. <i>Blood</i> , 2018, 131, 1464-1475.	1.4	57
21	Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. <i>Blood Advances</i> , 2021, 5, 2707-2716.	5.2	55
22	Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. <i>Journal of Clinical Oncology</i> , 2022, 40, 2352-2360.	1.6	53
23	Granulocyte colony-stimulating factor-induced blood stem cell mobilisation in patients with chronic heart failure. <i>Basic Research in Cardiology</i> , 2006, 101, 78-86.	5.9	52
24	Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 1053-1061.	1.3	49
25	Epigenetic Silencing of the Circadian Clock Gene CRY1 is Associated with an Indolent Clinical Course in Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2012, 7, e34347.	2.5	44
26	Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas – the PETAL trial. <i>Leukemia and Lymphoma</i> , 2009, 50, 1757-1760.	1.3	42
27	Significant Improvement Of Outcome In Adolescents and Young adults (AYAs) Aged 15-35 Years With Acute Lymphoblastic Leukemia (ALL) With a Pediatric Derived Adult ALL Protocol; Results Of 1529 AYAs In 2 Consecutive Trials Of The German Multicenter Study Group For Adult ALL (GMALL). <i>Blood</i> , 2013, 122, 839-839.	1.4	41
28	Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. <i>Blood Advances</i> , 2021, 5, 2375-2384.	5.2	40
29	Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma. <i>Cancer Immunology Research</i> , 2017, 5, 1122-1132.	3.4	38
30	Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2605-2616.	1.6	37
31	Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soramf Trial. <i>Blood</i> , 2014, 124, 6-6.	1.4	34
32	Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas – a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL) Tj ETQq0 0 0 rg Bit4 Overlock 10 Tf 50	1.4	34
33	Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the 18F SUV _{max} Method. <i>Journal of Nuclear Medicine</i> , 2021, 62, 37-42.	5.0	29
34	Progranulin Is a Novel Independent Predictor of Disease Progression and Overall Survival in Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2013, 8, e72107.	2.5	26
35	Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial. <i>Annals of Hematology</i> , 2019, 98, 897-907.	1.8	24
36	FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL >60 trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3550-3559.	6.4	21

#	ARTICLE	IF	CITATIONS
37	Favorable Outcome in a Large Cohort of Prospectively Treated Adult Patients with T-Lymphoblastic Lymphoma (T-LBL) Despite Slowly Evolving Complete Remission Assessed By Conventional Radiography. <i>Blood</i> , 2014, 124, 370-370.	1.4	19
38	Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial. <i>Hematological Oncology</i> , 2020, 38, 244-256.	1.7	18
39	Complement Inhibition with Eculizumab in Patients with Cold Agglutinin Disease (CAD): Results from a Prospective Phase II Trial (DECADE Trial). <i>Blood</i> , 2015, 126, 274-274.	1.4	17
40	Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG). <i>Leukemia</i> , 2019, 33, 439-446.	7.2	15
41	Gene Expression Profiles in Murine Hematopoietic Stem Cells Revisited: Analysis of cDNA Libraries Reveals High Levels of Translational and Metabolic Activities. <i>Stem Cells</i> , 2006, 24, 1719-1727.	3.2	11
42	Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLID-1 Trials. <i>Transplantation</i> , 2018, 102, 1914-1923.	1.0	11
43	Pitfalls of Interim Positron Emission Tomography Scanning in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, e488-e489.	1.6	9
44	A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial. <i>British Journal of Haematology</i> , 2022, 198, 482-491.	2.5	8
45	Efficacy of the GMALL-BALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin lymphomas with or without CNS involvement. <i>European Journal of Haematology</i> , 2019, 102, 241-250.	2.2	7
46	Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA). <i>Blood</i> , 2020, 136, 39-40.	1.4	6
47	Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome. <i>Blood Cancer Journal</i> , 2019, 9, 67.	6.2	5
48	Genetic Variants of the NKG2C/HLA-E Receptor-Ligand Axis Are Determinants of Progression-Free Survival and Therapy Outcome in Aggressive B-Cell Lymphoma. <i>Cancers</i> , 2020, 12, 3429.	3.7	5
49	Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy. <i>Cancer Medicine</i> , 2020, 9, 8386-8396.	2.8	5
50	Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis. <i>British Journal of Haematology</i> , 2022, 198, 401-404.	2.5	5
51	Rapid succession of peripheral blood progenitor cell mobilization cycles in patients with chronic heart failure: effects on the hematopoietic system. <i>Transfusion</i> , 2006, 46, 1424-1431.	1.6	4
52	Prognostic Significance of Molecular Remission in Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, e613-e613.	1.6	4
53	Treatment Outcome in Patients with Primary or Secondary Transformed Indolent B-Cell Lymphomas. <i>Oncology Research and Treatment</i> , 2019, 42, 580-588.	1.2	4
54	Serologic response to meningococcal vaccination in patients with cold agglutinin disease (CAD) in the novel era of complement inhibition. <i>Vaccine</i> , 2019, 37, 6682-6687.	3.8	4

#	ARTICLE	IF	CITATIONS
55	Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 95.	6.2	4
56	AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial. <i>Blood</i> , 2020, 136, 31-32.	1.4	4
57	Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabine and cisplatin in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD15). <i>British Journal of Haematology</i> , 2022, 196, 606-616.	2.5	4
58	Metabolic tumor volume, cancer cell fraction, and prognosis – the case of T-cell/histiocyte-rich large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1372-1379.	1.3	3
59	Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial. <i>Blood</i> , 2020, 136, 6-7.	1.4	3
60	Polyclonal Free Light Chain Elevation and Mortality In the German Heinz Nixdorf Recall Study. <i>Blood</i> , 2010, 116, 3903-3903.	1.4	3
61	Reply to J. Wang et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 755-757.	1.6	2
62	The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World. <i>Blood</i> , 2020, 136, 30-31.	1.4	2
63	Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2611-2621.	2.5	2
64	Supporting data for positron emission tomography-based risk modelling using a fixed-instead of a relative thresholding method for total metabolic tumor volume determination. <i>Data in Brief</i> , 2020, 28, 104976.	1.0	1
65	Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma: A Phase II Trial (GOAL). <i>Blood</i> , 2018, 132, 1678-1678.	1.4	1
66	Prevalence of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Light-Chain MGUS (LCMGUS) In a Metropolitan Area In Germany. <i>Blood</i> , 2010, 116, 4037-4037.	1.4	1
67	Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 2838-2838.	1.4	1
68	Porphyria cutanea tarda. <i>British Journal of Haematology</i> , 2010, 148, 493-493.	2.5	0
69	Reply to H.J.A Adams et al and C. Gisselbrecht. <i>Journal of Clinical Oncology</i> , 2018, 36, 3273-3274.	1.6	0
70	Outcomes of Primary and Secondary Transformed B-Cell Lymphomas. <i>Blood</i> , 2015, 126, 3894-3894.	1.4	0
71	Immunoglobulin M Heavy/Light Chain Pair Measurement Independently Predicts Clinical Outcome and Refines Prognostic Information Provided By Interim PET in Patients with Aggressive Lymphomas. <i>Blood</i> , 2015, 126, 3880-3880.	1.4	0
72	Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. <i>Blood</i> , 2018, 132, 2861-2861.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Interim PET-Based Outcome Prediction in Diffuse Large B-Cell Lymphoma Patients Participating in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) Trial: Comparison of the Delta SUV Max Method and the Deauville 5-Point Scale. <i>Blood</i> , 2018, 132, 1696-1696.	1.4	0
74	Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. <i>Blood</i> , 2018, 132, 4188-4188.	1.4	0